JNJ vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
Microsoft Corporation · Technology
$379.40
+45.0% upside to fair value
Grade A
High Quality
QuantHub Verdict
MSFT has more upside to fair value
(+45.0%).
MSFT trades at a lower forward P/E
(22.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
MSFT |
| Current Price |
$253.85 |
$379.40 |
| Fair Value Estimate |
$198.76 |
$550.13 |
| Upside to Fair Value |
-21.7%
|
+45.0%
|
| Market Cap |
$611.1B |
$2,818.3B |
| Forward P/E |
29.3x
|
22.5x
|
| EV / EBITDA |
19.2x
|
14.2x
|
| Price / Sales |
6.3x
|
8.9x
|
| Price / FCF |
34.3x
|
38.6x
|
| Revenue Growth YoY |
+9.9%
|
+18.3%
|
| Gross Margin |
69.1%
|
68.3%
|
| Operating Margin |
26.9%
|
46.8%
|
| Return on Equity |
26.3%
|
33.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
2.59%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Microsoft Corporation is a leading global technology company specializing in cloud computing, productivity software, and enterprise platforms. The company benefits from a very strong and widening competitive moat supported by scale, switching costs, an integrated ecosystem, and disciplined capital allocation including large buybacks and dividends. Its business quality is high, demonstrated by a 3…
Accumulation Zones
| Metric |
JNJ |
MSFT |
| Zone Low |
$149.07 |
$412.60 |
| Zone High |
$168.95 |
$467.61 |
| In Buy Zone? |
No
|
Yes
|